Skip to main content
SpringerLink
Log in

Antianämika

  • Chapter
Arzneiverordnungs-Report 2013

  • 1726 Accesses

Zusammenfassung

Eine Anämie kann zahlreiche Ursachen haben, die vor Beginn der Therapie mit Antianämika geklärt werden sollten. Am häufigsten ist die Eisenmangelanämie durch mangelnde Zufuhr, ungenügende Resorption, gesteigerten Bedarf oder Verlust von Eisen z. B. durch okkulte Blutungen. Daneben gibt es sekundäre Anämien bei Leber- oder Nierenkrankheiten, Tumoren, Infektionen oder Zytostatikatherapie sowie weitere Anämieformen mit gestörter Erythrozytenbildung (z. B. aplastische Anämie) und mit gesteigertem Erythrozytenabbau (hämolytische Anämien verschiedener Art). Bei älteren Patienten kann die Prävalenz der Anämie bis zu 40% ansteigen (Röhrig et al. 2012).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Baker WF, Bick RL (1999): Treatment of hereditary and acquired thrombophilic disorders. Semin Thromb Hemost 25: 387–406.

    Article  PubMed  CAS  Google Scholar 

  • Auerbach M, Ballard H (2010): Clinical use of intravenous iron: administration, efficacy, and safety. Hematology Am Soc Hematol Educ Program: 338–347.

    Google Scholar 

  • Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J, Zwahlen M, Clarke M, Weingart O, Kluge S, Piper M, Rades D, Steensma DP, Djulbegovic B, Fey MF, Ray-Coquard I, Machtay M, Moebus V, Thomas G, Untch M, Schumacher M, Egger M, Engert A (2009): Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 373: 1532–1542.

    Article  PubMed  CAS  Google Scholar 

  • Bonaa KH, Njolstad I, Ueland PM, Schirmer H, Tverdal A et al (NORVIT Trial Investigators) (2006): Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354: 1578-1588.

    Google Scholar 

  • Büchner T (2003): Anämien. In: Therapie Innerer Krankheiten (Hrsg Paumgartner G, Steinbeck G). Springer-Verlag Berlin, Heidelberg, New York, 10. Aufl., S. 1015.

    Google Scholar 

  • Curran MP, McCormack PL (2008): Methoxy polyethylene glycol-epeoetin beta: a review of ist use in the management of anaemia associated with chronic kidney disease. Drugs 68: 1139–1156.

    Article  PubMed  CAS  Google Scholar 

  • Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Mcdougall IC et al. (2006): Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: 2071–2084.

    Article  PubMed  Google Scholar 

  • Dührsen U (2002): Gibt es Indikationen für Erythropoetin in der Onkologie? Dtsch Ärztebl 99: A3470–A3475.

    Google Scholar 

  • European Medicines Agency (2008): Questions and answers on epoetins and risk of tumor growth and blood clots in the vein. Internet: www.ema.europa.eu/docs/en_GB/document_library/Medicine_QA/2009/11/WC500015145.pdf

  • Fishbane S, Frei GL, Maesaka J (1995): Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26: 41–46.

    Article  PubMed  CAS  Google Scholar 

  • Fishbane S (2003): Safety in iron management. Am J Kidney Dis 41 (5 Suppl): 18–26.

    Article  PubMed  Google Scholar 

  • Fishbane S, Mittal SK, Maesaka JK (1999): Beneficial effects of iron therapy in renal failure patients on hemodialysis. Kidney Int 55: 67–70.

    Article  Google Scholar 

  • Food and Drug Administration (2007): Information for Healthcare Professionals November 8, 2007. Erythropoesis stimulating agents (ESA). Internet: www.fda.gov/cder/drug/InfoSheets/HCP/RHE200711HCP.htm

  • Hanley DF (2004): The challenge of stroke prevention. JAMA 291: 621–622.

    Article  PubMed  CAS  Google Scholar 

  • Heinrich HC (1986): Bioverfügbarkeit und therapeutischer Wert oraler Eisen(II)- und Eisen(III)-Präparate. Dtsch Apoth Ztg 126: 681–690.

    Google Scholar 

  • Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H (2003): Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebocontrolled trial. Lancet 362: 1255–1260.

    Article  PubMed  CAS  Google Scholar 

  • Hermann W, Obeid R (2011): Die obligatorische Folsäurefortifikation von Nahrungsmitteln. Ein in Deutschland kontrovers diskutiertes Thema. Dtsch Ärztebl 108: 249–254.

    Google Scholar 

  • Homocysteine Studies Collaboration (2002): Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 288: 2015–2022.

    Google Scholar 

  • Hörl WH, Vanrenterghem Y (2005): Optimal treatment of renal anaemia (OPTA): improving the efficacy and efficiency of renal anaemia therapy in haemodialysis patients receiving intravenous epoetin. NephrolDialTransplant 20, Suppl.3: iii25–32.

    Google Scholar 

  • Ibbotson T, Goa KL (2001): Darbepoetin alfa. Drugs 61: 2097–2104.

    Article  PubMed  CAS  Google Scholar 

  • Kaltwasser JP (2003): Eisenmangelanämie. In: Berdel WE, Böhm M, Classen M, Diehl V, Kochsiek K, Schmigel W (Hrsg): Innere Medizin. 5. Auflage, Urban & Fischer, München Jena, S. 706–711.

    Google Scholar 

  • Kaltwasser JP, Werner E, Niechzial M (1987): Bioavailability and therapeutic efficacy of bivalent and trivalent iron preparations. Arzneim Forsch 37: 122–129.

    CAS  Google Scholar 

  • Kaufman JS, Reda DJ, Fye CL, Goldfarb DS, Henderson WG et al. (1998): Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. N Engl J Med 339: 578–583.

    Article  PubMed  CAS  Google Scholar 

  • Koletzko B, Pietrzik K (2004): Gesundheitliche Bedeutung der Folsäurezufuhr. Dtsch Ärztebl 101: A 1670–1681.

    Google Scholar 

  • Lange H, Suryapranata H, De Luca G, Böner C, Dille J, Kallmayer K et al (2004): Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 350: 2673–2681.

    Article  PubMed  CAS  Google Scholar 

  • Leyland-Jones B; BEST Investigators and Study Group (2003): Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 4: 459–460.

    Google Scholar 

  • Liu K, Kaffes AJ (2012): Iron deficiency anaemia: a review of diagnosis, investigation and management. Eur J Gastroenterol Hepatol 24: 109–116.

    Article  PubMed  CAS  Google Scholar 

  • MacDougall IC (1999): Strategies for iron supplementation: Oral versus intravenous. Kidney Int 55: 61–66.

    Article  Google Scholar 

  • Marsh WA, Rascati KL (1999): Meta-analyses of the effectiveness of erythropoetin for end-stage renal disease and cancer. Clin Ther 21: 1443–1455.

    Article  PubMed  CAS  Google Scholar 

  • Röhrig G, Doehner W, Schaefer RM, Schulz RJ (2012): Anämie und Eisenmangel in der Geriatrie. Prävalenz, Diagnostik und neue Therapieoptionen. Z Gerontol Geriatr 45: 191–196.

    Article  PubMed  Google Scholar 

  • Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S et al. (2006): Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: 2085–2098.

    Article  PubMed  CAS  Google Scholar 

  • Steffensen GK, Stergaard O (2011): Administration of the same dose of epoetin-beta intravenously subcutaneously to patients with renal anaemia. Scand J Urol Nephrol 45: 461–469.

    Article  PubMed  CAS  Google Scholar 

  • The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006): Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354: 1567–1577.

    Google Scholar 

  • Thomas L, Thomas C, Heimpel H (2005): Neue Parameter zur Diagnostik von Eisenmangelzuständen. Dtsch Ärztebl 102: A 580–586.

    Google Scholar 

  • Tonia T, Mettler A, Robert N, Schwarzer G, Seidenfeld J, Weingart O, Hyde C, Engert A, Bohlius J (2012): Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev. 2012 Dec 12; 12: CD003407.

    Google Scholar 

  • Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC et al (2004): Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarktion, and death: the vitamin intervention for stroke prevention (VISP). JAMA 291: 565–575.

    Article  PubMed  CAS  Google Scholar 

  • Wald NJ (2004): Folic acid and the prevention of neural-tube defects. N Engl J Med 350: 101–103.

    Article  PubMed  CAS  Google Scholar 

  • Weiss LG, Clyne N, Divino Fihlho J, Frisenette-Fich C, Kurkus J, Svensson B (2000): The efficacy of once weekly compared with two or three times weekly subcutaneous epoetin ß: results from a randomized controlled multicentre trial. Swedish Study Group. Nephrol Dial Transplant 15: 2014–2019.

    Article  PubMed  CAS  Google Scholar 

  • Wollenberg P (2009): Eisen – Pharmakotherapie des Eisenmangels. In: Allgemeine und spezielle Pharmakologie und Toxikologie (Hrsg. Aktories K, Förstermann U, Hofmann F, Starke K) Urban & Fischer Verlag München, Jena, 10. Aufl, S. 741–751.

    Google Scholar 

  • Zhou SJ, Gibson RA, Crowther CA, Makrides M (2009): Should we lower the dose of iron when treating anaemia in pregnancy? A randomized dose-response trial. Eur J Clin Nutr 63: 183–190.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Mannheim, Höferstraße 15, 68199

    Dr. med. Klaus Mengel

Authors
  1. Dr. med. Klaus Mengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut, der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. AOK NORDWEST Die Gesundheitskasse, Edisonstraße 70, 24145, Kiel

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Mengel, K. (2013). Antianämika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2013. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-37124-0_8

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-37124-0_8

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-37123-3

  • Online ISBN: 978-3-642-37124-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation